Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis
Conditions
Interventions
GDC-229
Metronidazole Vaginal Gel 0.75%
+1 more
Locations
1
United States
Site 103
Raleigh, North Carolina, United States
Start Date
March 10, 2017
Primary Completion Date
November 15, 2017
Completion Date
March 27, 2018
Last Updated
January 7, 2020
NCT07394777
NCT06472765
NCT06469164
NCT06470906
NCT06123299
NCT02432404
Lead Sponsor
Balmoral Medical company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions